利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.019 秒)

    KNOCKOUT ANIMAL EXHIBITING ANXIETY-LIKE BEHAVIOR
    2.
    发明申请
    KNOCKOUT ANIMAL EXHIBITING ANXIETY-LIKE BEHAVIOR 审中-公开
    KNOCKOUT动画展示类似动作的行为

    公开(公告)号：US20100050277A1

    公开(公告)日：2010-02-25

    申请号：US12515064

    申请日：2007-11-16

    申请人： Tamotsu Hashimoto ,  Atsushi Tsujimura

    发明人： Tamotsu Hashimoto ,  Atsushi Tsujimura

    IPC分类号： G01N33/50 ,  A01K67/027 ,  C12N15/85 ,  C12N15/74

    CPC分类号： C07K14/47 ,  A01K67/0276 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/0356 ,  C12N15/8509 ,  C12N2800/30

    摘要： A vector for creating kf-1 gene knockout nonhuman animals exhibiting increased anxiety-like behaviors, and containing Lox-pM-M-kf-1[in3b]-kf-1[ex4a]-LoxP,(wherein, M is a selection marker gene, pM is a promoter for the expression of the selection marker gene, kf-1[in3b] is a sequence represented by SEQ ID NO: 2, and kf-1[ex4a] is a sequence represented by SEQ ID NO: 3); kf-1 gene knockout nonhuman animals exhibiting increased anxiety-like behaviors produced by using the vector or a descendant of the animal, and a method for use of the same.

    摘要翻译： 用于产生kf-1基因敲除非人动物表现出增加的焦虑样行为的载体，并含有Lox-pM-M-kf-1 [in3b] -kf-1 [ex4a] -LoxP（其中，M是选择标记 基因，pM是选择标记基因表达的启动子，kf-1 [in3b]是由SEQ ID NO：2表示的序列，kf-1 [ex4a]是由SEQ ID NO：3表示的序列） ; kf-1基因敲除非人动物表现出通过使用该动物的载体或后代产生的焦虑样行为及其使用方法。

    ABA tri-block copolymer
    6.
    发明授权
    ABA tri-block copolymer 失效
    ABA三嵌段共聚物

    公开(公告)号：US07435782B2

    公开(公告)日：2008-10-14

    申请号：US11799676

    申请日：2007-05-02

    申请人： Tamotsu Hashimoto ,  Takeshi Namikoshi ,  Michio Urushisaki

    发明人： Tamotsu Hashimoto ,  Takeshi Namikoshi ,  Michio Urushisaki

    IPC分类号： C08F297/00 ,  C08F4/10

    CPC分类号： C08F232/08

    摘要： An ABA tri-block copolymer represented by the following formula (1) [in the formula (1), n and m are each independently an integer of 30 to 1,000]. The copolymer is a so-called ABA tri-block copolymer between 8-vinyloxytricyclo [5.2.1.02.6] decane and n-butyl vinyl ether, has rubber elasticity at normal temperature, and has a property of thermoplastic elastomer which has not been possessed by conventional vinyl ether copolymers.

    摘要翻译： 由下式（1）表示的ABA三嵌段共聚物[式（1）中，n和m各自独立地为30〜1000的整数]。 共聚物是8-乙烯基氧三环[5.2.1.0]癸烷和正丁基乙烯基醚之间的所谓ABA三嵌段共聚物，在常温下具有橡胶弹性，并具有热塑性 常规乙烯基醚共聚物尚未具有的弹性体。

    ABA tri-block copolymer
    7.
    发明申请
    ABA tri-block copolymer 失效
    ABA三嵌段共聚物

    公开(公告)号：US20080114141A1

    公开(公告)日：2008-05-15

    申请号：US11799676

    申请日：2007-05-02

    申请人： Tamotsu Hashimoto ,  Takeshi Namikoshi ,  Michio Urushisaki

    发明人： Tamotsu Hashimoto ,  Takeshi Namikoshi ,  Michio Urushisaki

    IPC分类号： C08F16/12

    CPC分类号： C08F232/08

    摘要： An ABA tri-block copolymer represented by the following formula (1) [in the formula (1), n and m are each independently an integer of 30 to 1,000].The copolymer is a so-called ABA tri-block copolymer between 8-vinyloxytricyclo[5.2.1.02.6]decane and n-butyl vinyl ether, has rubber elasticity at normal temperature, and has a property of thermoplastic elastomer which has not been possessed by conventional vinyl ether copolymers.

    摘要翻译： 由下式（1）表示的ABA三嵌段共聚物[式（1）中，n和m各自独立地为30〜1000的整数]。 共聚物是8-乙烯基氧三环[5.2.1.0]癸烷和正丁基乙烯基醚之间的所谓ABA三嵌段共聚物，在常温下具有橡胶弹性，并具有热塑性 常规乙烯基醚共聚物尚未具有的弹性体。

    Dibenz [b,e] oxepin derivatives
    8.
    发明授权
    Dibenz [b,e] oxepin derivatives 失效
    二苯并[b，e]氧杂七环衍生物

    公开(公告)号：US4465835A

    公开(公告)日：1984-08-14

    申请号：US486425

    申请日：1983-04-19

    申请人： Hiroshi Takizawa ,  Osamu Morita ,  Yoshimasa Oiji ,  Tamotsu Hashimoto

    发明人： Hiroshi Takizawa ,  Osamu Morita ,  Yoshimasa Oiji ,  Tamotsu Hashimoto

    IPC分类号： C07D313/12 ,  C07D453/02 ,  C07D491/10 ,  C07D405/04

    CPC分类号： C07D491/10 ,  C07D313/12 ,  C07D453/02

    摘要： Novel dibenz [b,e] oxepin derivatives represented by the general formula: ##STR1## wherein R.sub.11 represents an alkyl group containing 1 to 5 carbon atoms, an alkoxy group containing 1 to 5 carbon atoms, a halogen atom, a cyclohexyl group or a phenyl group; and R.sub.21 represents ##STR2## wherein X represents a hydrogen atom, a hydroxy group, an amino group or a substituted aralkyl group containing 7 to 20 carbon atoms, and n represents 0 or an integer of 1 to 3 ##STR3## wherein Y represents an alkylamino group containing 1 to 5 carbon atoms, an aralkyl group containing 7 to 20 carbon atoms, a substituted aralkyl group, an aralkyloxy group containing 7 to 20 carbon atoms, an aralkylamino group containing 7 to 20 carbon atoms, a heterocyclic ring or a substituted heterocyclic ring, and n has the same meaning as defined before; provided that when R.sub.11 represents an alkyl group, an alkoxy group or a halogen atom, X does not represent a hydrogen atom; and the pharmaceutically acceptable acid addition salts thereof.Also disclosed are pharmaceutical compositions comprising a pharmaceutical carrier and, as an active ingredient, an effective amount of dibenz [b,e] oxepin derivative represented by the following general formula: ##STR4## wherein R.sub.1 represents an alkyl group containing 1 to 5 carbon atoms, an alkoxy group containing 1 to 5 carbon atoms, a halogen atom, a cyclohexyl group or a phenyl group; and R.sub.2 represents ##STR5## wherein X represents a hydrogen atom, a hydroxy group, an amino group or a substituted aralkyl group containing 7 to 20 carbon atoms, and n has the same meaning as defined before ##STR6## wherein Y and n have the same meaning as defined above; and the pharmaceutically acceptable acid addition salts thereof. Compound I, represented by the general formula (I), has antichlolinergic, antihistaminergic, antiasthmatic and antiplatelet aggregation activities, and is therefore useful as a sposmolysant, an antihistaminic, an antiasthmatic agent and as a medicament for cardiovascular or cerebrovascular diseases, respectively.This is a division of application Ser. No. 256,037, filed Apr. 21, 1981, now U.S. Pat. No. 4,396,550.

    Dibenz [b,e] oxepin derivatives
    9.
    发明授权
    Dibenz [b,e] oxepin derivatives 失效

    公开(公告)号：US4396550A

    公开(公告)日：1983-08-02

    申请号：US256037

    申请日：1981-04-21

    申请人： Hiroshi Takizawa ,  Osamu Morita ,  Yoshimasa Oiji ,  Tamotsu Hashimoto

    发明人： Hiroshi Takizawa ,  Osamu Morita ,  Yoshimasa Oiji ,  Tamotsu Hashimoto

    IPC分类号： C07D313/12 ,  C07D453/02 ,  C07D491/10 ,  C07D301/00 ,  A61K31/36 ,  C07D303/00 ,  C07D305/00

    CPC分类号： C07D491/10 ,  C07D313/12 ,  C07D453/02

    摘要： Novel dibenz [b,e] oxepin derivatives represented by the general formula: ##STR1## wherein R.sub.11 represents an alkyl group containing 1 to 5 carbon atoms, an alkoxy group containing 1 to 5 carbon atoms, a halogen atom, a cyclohexyl group or a phenyl group; and R.sub.21 represents ##STR2## wherein X represents a hydrogen atom, a hydroxy group, an amino group or a substituted aralkyl group containing 7 to 20 carbon atoms, and n represents 0 or an integer of 1 to 3 ##STR3## or (3) --NH--(CH.sub.2).sub.n --Y, wherein Y represents an alkylamino group containing 1 to 5 carbon atoms, an aralkyl group containing 7 to 20 carbon atoms, a substituted aralkyl group, an aralkyloxy group containing 7 to 20 carbon atoms, an aralkylamino group containing 7 to 20 carbon atoms, a heterocyclic ring or a substituted heterocyclic ring, and n has the same meaning as defined before; provided that when R.sub.11 represents an alkyl group, an alkoxy group or a halogen atom, X does not represent a hydrogen atom; and the pharmaceutically acceptable acid addition salts thereof.Also disclosed are pharmaceutical compositions comprising a pharmaceutical carrier and, as an active ingredient, an effective amount of a dibenz [b,e] oxepin derivative represented by the following general formula: ##STR4## wherein R.sub.1 represents an alkyl group containing 1 to 5 carbon atoms, an alkoxy group containing 1 to 5 carbon atoms, a halogen atom, a cyclohexyl group or a phenyl group; and R.sub.2 represents ##STR5## wherein X represents a hydrogen atom, a hydroxy group, an amino group or a substituted aralkyl group containing 7 to 20 carbon atoms, and n has the same meaning as defined before ##STR6## or (3) --NH--(CH.sub.2).sub.n --Y, wherein Y and n have the same meaning as defined above; and the pharmaceutically acceptable acid addition salts thereof. Compound I, represented by the general formula (I), has antichlolinergic, antihistaminergic, antiasthmatic and antiplatelet aggregation activities, and is therefore useful as a sposmolysant, an antihistaminic, an antiasthmatic agent and as a medicament for cardiovascular or cerebrovascular diseases, respectively.